Clinical guidelines have recommended the use of tamoxifen and aromatase inhibitors (AI) as adjuvant endocrine therapy options for postmenopausal women with ER(+) breast cancer [6, 7]. The gene discussed is CYP19A1; the disease is breast carcinoma.